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 23 
Abstract 24 
Tumor relapse and metastatic spreading act as major hindrances to achieve complete cure of breast 25 
cancer. Evidence suggests that cancer stem cells (CSC) would function as a reservoir for the local 26 
and distant recurrence of the disease, due to their resistance to radio- and chemotherapy and their 27 
ability to regenerate the tumor. Therefore, the identification of appropriate molecular targets 28 
expressed by CSC may be critical in the development of more effective therapies. 29 
Our studies focused on the identification of mammary CSC antigens and on the development of 30 
CSC-targeting vaccines. We compared the transcriptional profile of CSC-enriched tumorspheres 31 
from an Her2+ breast cancer cell line with that of the more differentiated parental cells. Among the 32 
molecules strongly upregulated in tumorspheres we selected the transmembrane amino-acid 33 
antiporter xCT.  34 
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In this review, we summarize the results we obtained with different xCT-targeting vaccines. We 1 
show that, despite xCT being a self-antigen, vaccination was able to induce a humoral immune 2 
response that delayed primary tumor growth and strongly impaired pulmonary metastasis formation 3 
in mice challenged with tumorsphere-derived cells. Moreover, immunotargeting of xCT was able to 4 
increase CSC chemosensitivity to doxorubicin, suggesting that it may act as an adjuvant to 5 
chemotherapy. 6 
In conclusion, our approach based on the comparison of the transcriptome of tumorspheres and 7 
parental cells allowed us to identify a novel CSC-related target and to develop preclinical therapeutic 8 
approaches able to impact on CSC biology and therefore hampering tumor growth and dissemination. 9 
 10 
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Précis 14 
Anti-CSC vaccination through targeting of the xCT transporter elicits protective immunity against 15 
mammary tumor challenge and metastasis formation in a preclinical setting. 16 
 17 
Abbreviations 18 
ADCC antibody-dependent cell cytotoxicity 19 
ALDH aldehyde dehydrogenase 20 
BoHV-4 bovine herpesvirus-4 21 
CSC cancer stem cell 22 
ECD extracellular domain 23 
GSH glutathione 24 
ROS reactive oxygen species 25 
SASP sulfasalazine 26 
VLP Virus-Like Particles  27 
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Chemotherapy and radiotherapy have represented the treatments of choice for cancer patients in 1 
the past decades, often affording reduction in the tumor burden. However, a minority of cells, named 2 
cancer stem cells (CSC), has been shown to be more resistant to such therapies compared to more 3 
differentiated cancer cells of the same tumor [1], thus contributing to treatment failure and to local 4 
and distant recurrence. CSC possess the capacity to self-renew and to generate the heterogeneous 5 
lineages of cancer cells that compose the tumor, in a process that mimics normal tissue development 6 
[2]. They can be experimentally defined by their exclusive ability to recapitulate the generation of a 7 
continuously growing tumor even when injected at low cell density [2], and are thus operatively 8 
referred to as “tumor-initiating cells”, while more differentiated cells lack this ability. 9 
From a clinical perspective, the CSC concept has significant implications. As mentioned above, 10 
conventional anticancer approaches are predominantly directed against the bulk population of the 11 
tumor but are not effective against CSC, because of mechanisms such as increased drug efflux and 12 
detoxification, thus allowing this self-renewing cell population to cause the perpetuation of the tumor 13 
[3]. Therefore, approaches targeting CSC could increase the long-term efficacy of currently available 14 
treatments. The potential of immunotherapy against CSC has recently become an intriguing field of 15 
research. The idea is that immune effectors not only may succeed where chemotherapy fails, but can 16 
also block the molecules involved in the chemoresistance mechanisms. Moreover, some evidence 17 
suggests that CSC are a superior target for immunotherapy compared to non-CSC. In the preclinical 18 
setting, loading DC with CSC lysates induced protective antitumor immunity in immunocompetent 19 
mice, while bulk tumor-loaded DC were unable to afford the same results [4]. This can be attributed to 20 
the fact that CSC and more differentiated cancer cells express different antigens because of their 21 
different gene expression profiles. Therefore, immunologic approaches directed against whole tumors 22 
are largely biased toward differentiated cancer cells, which represent the major proportion of the 23 
tumor mass and express tolerated differentiation antigens [4]. This might mask immunologic 24 
responses to tumor-perpetuating CSC, which represent only a minor percentage of tumor cells. CSC 25 
thus appear to be a better source of antigens compared to non-CSC, and their ablation requires a 26 
specific targeting. 27 
These encouraging preclinical results led to the translation of CSC-loaded DC vaccines into the 28 
clinic, showing that they were safe, able to induce an immune response in all treated patients and to 29 
improve progression-free survival compared to unvaccinated controls [5]. However, in none of the 30 
reported anti-CSC vaccination approaches specific CSC-antigens were identified, as DC were loaded 31 
with whole protein or mRNA derived from tumor cells. This type of treatment is patient-specific and 32 
at the current state requires high manufacturing costs, thus hampering its large-scale usage [3]. Other 33 
limitations of DC-based personalized vaccines, including the difficulty in setting up standardized 34 
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procedures, ensuring the proper maturation status of the DC and the precise selection of appropriate 1 
DC subsets required to elicit the desired response, may eventually impair the efficacy of the treatment 2 
[6]. 3 
On the contrary, a large-scale clinical benefit could be achieved by combining a vaccine 4 
formulation that is cost-effective and highly reproducible, and a target antigen that is shared among 5 
a large number of patients. In this context, we coined the term “oncoantigens” to indicate tumor-6 
associated molecules that have a causal role in the promotion of carcinogenesis and cannot be easily 7 
down-modulated or negatively selected by cancer cells under the pressure of a specific immune attack 8 
[7]. When expressed on the cell membrane they can be the target of both cell-mediated and antibody-9 
mediated immune responses. Therefore, greater efficacy for immunotherapy could be achieved by 10 
targeting transmembrane oncoantigens expressed by CSC by virtue of their role in the progression, 11 
metastasis, resistance to therapy, and recurrence of tumors [8].  12 
 13 
Identification of CSC oncoantigens 14 
An ideal antigen should be derived from a non-dispensable protein, in this case a protein required 15 
for CSC survival, self-renewal and tumor-initiating ability. However, no consensus exists on the 16 
expression of specific oncoantigens by CSC.  17 
To fill this gap, we developed a pipeline to identify CSC oncoantigens. Initially, high-throughput 18 
transcription analysis is used to highlight the gene signatures that distinguish CSC from more 19 
differentiated cancer cells. Of the upregulated transcripts in CSC, which are more likely to have a 20 
functional role in their biology, only those that have an orthologue in humans, low expression in 21 
normal human tissues, high expression in human cancers and association with poor prognosis are 22 
selected as “putative” oncoantigens [9]. These candidate oncoantigens are eventually validated by 23 
immunizing tumor-bearing mice with vaccines targeting them. 24 
Besides the sorting based on CSC markers expression such as CD44, CD24 [10], Sca-1 [11] and 25 
aldehyde dehydrogenase (ALDH) activity [12], a tool often employed for propagating CSC 26 
populations is represented by the generation of “tumorspheres”, spherical anchorage-independent cell 27 
clones growing in serum-free medium supplemented with factors that favor stem cell growth [13]. 28 
Given the exclusive ability of CSC to survive and grow under these conditions, tumorsphere 29 
generation has gained popularity as an in vitro surrogate assay substituting the more time and money 30 
consuming tumor-initiation assay, and has been developed for a wide range of solid tumors, including 31 
breast cancer [14].  32 
To identify oncoantigens expressed by mammary CSC, we performed a comparative 33 
transcriptomic analysis between cells cultured as monolayer and cells cultured as tumorspheres. For 34 
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this purpose, we used the TUBO cell line, established from a Her2+ mammary tumor arisen in a 1 
BALB/c female mouse transgenic for the rat Her2/neu oncogene (BALB-neuT) [15]. Serial passages 2 
of TUBO tumorspheres displayed increasing clonogenic potential, as well as a higher tumor-initiating 3 
ability, compared to TUBO cells grown as monolayer. Furthermore, tumorspheres showed stronger 4 
positivity for several CSC markers including Sca-1, Nanog, Oct-4 and ALDH activity [9]. All these 5 
observations strongly suggest that tumorspheres derived from TUBO cells are enriched in CSC. 6 
Focusing on genes strongly upregulated in tumorspheres and coding for proteins expressed on cell 7 
surface [9, 16], we selected xCT.  8 
 9 
xCT oncoantigen and its role in breast CSC 10 
xCT is a multipass transmembrane protein of ~500 amino-acids encoded by the gene Solute 11 
Carrier Family 7, Member 11 (SLC7A11). It consists of 12 transmembrane, 7 intracellular and 6 12 
extracellular domains, with both the N- and C- termini located inside the cell (Figure 1). xCT is the 13 
light subunit of the heterodimeric amino-acid transport system xc- and is coupled through a disulfide 14 
bond to the heavy subunit 4F2hc, also termed CD98 [17]. While CD98 is responsible for the 15 
trafficking of the heterodimer to the plasma membrane and acts as a subunit for several other amino 16 
acid transporters, xCT is responsible for substrate specificity and transport. System xc- is an obligate, 17 
Na+-independent antiporter that exports intracellular glutamate in exchange for extracellular cystine 18 
in a gradient-dependent manner and 1:1 ratio [17]. Once inside the cell, cystine is reduced to cysteine, 19 
the rate-limiting precursor in the biosynthesis of glutathione (GSH). GSH plays a critical role in 20 
cellular defenses against oxidative stress, as it can reduce diverse reactive oxygen species (ROS). 21 
Albeit ROS are essential for biological functions, as they regulate many signaling pathways, an 22 
imbalance of ROS content within the cell can lead to harmful effects, since they can mediate an 23 
oxidative modification of biological molecules, including DNA, proteins and lipids, impairing their 24 
functions. This may result in transient cellular alterations, up to irreversible oxidative damage and 25 
cell death [18]. By providing precursors for GSH synthesis, system xc- mediates free radical 26 
scavenging and detoxification, thus playing a pivotal role in intracellular redox balance regulation.  27 
In our work, we have demonstrated that xCT is expressed at high levels in many cancerous human 28 
tissues compared to healthy samples from different organs [19]. Concerning mammary tissues, we 29 
observed that xCT expression is low in normal mammary gland, while it significantly increases in 30 
hyperplastic mammary tissue and invasive ductal breast carcinoma of different histological subtypes 31 
(Her2+, estrogen receptor/progesterone receptor+Her2-, triple negative). Here, xCT expression is 32 
confined to tumor cells, suggesting that xCT upregulation in the mammary tissue only occurs upon 33 
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oncogenic transformation. Moreover, high xCT levels in breast cancer negatively impact on patients’ 1 
overall survival [20]. 2 
In TUBO cells, the highest percentage of xCT+ cells is found in the CD44+/CD24- CSC fraction 3 
[19]. Furthermore, xCT expression increases progressively from cells growing as monolayer to cells 4 
derived from subsequent generations of tumorspheres, where the majority of Sca-1+ cells are also 5 
positive for xCT. xCT upregulation in tumorsphere-derived cells was observed not only in the TUBO 6 
cell line but also in other mouse and human mammary cancer cell lines, indicating that xCT 7 
expression increases in breast CSC [19]. Notably, inhibition of system xc- leads to decreased 8 
tumorsphere-forming ability in both mouse and human mammary cancer cell lines [21]. 9 
Given its detoxifying role, system xc- dysfunction in cancer models has been linked mainly to the 10 
induction of ROS-dependent cell death [22]. By virtue of their increased xCT expression, TUBO 11 
tumorspheres display significantly higher GSH and lower ROS content compared to cells grown as 12 
monolayer [19]. However, xCT silencing in tumorspheres brings their GSH and ROS content back to 13 
the levels observed in parental cells, leading to impaired tumorsphere-generation ability and 14 
decreased CSC marker expression [19]. xCT thus appears to play a central role in the maintenance of 15 
the CSC-state rather than in maintaining tumor cell biology under differentiating conditions, since 16 
xCT silencing does not affect proliferation of TUBO cells growing as monolayer but only of those 17 
growing as tumorspheres [19]. 18 
System xc- activity can be pharmacologically inhibited by the non-substrate inhibitor sulfasalazine 19 
(SASP). SASP is an FDA- and EMA-approved drug commonly used to treat chronic inflammatory 20 
diseases such as rheumatoid arthritis; it is also a potent inhibitor of NF-κB activation. However, it is 21 
insoluble in aqueous solutions and not optimized for the fortuitous interaction with xCT [23]. 22 
Moreover, significant side effects associated to the use of SASP occur in 25% of treated patients, and 23 
interruption of a clinical trial due to adverse events on glioma patients has been reported [24]. In 24 
general, no specific inhibitor of system xc- has been discovered yet, since all the studied compounds 25 
have shown off-target effects [17]. 26 
In this light, anti-xCT vaccination would provide a specific approach able to potently target xCT 27 
while at the same time avoiding undesired off-target effects.  28 
 29 
Development of anti-xCT vaccines 30 
Based on the central role played by xCT in mammary CSC biology, we developed multiple 31 
vaccination strategies to target xCT and impair mammary cancer progression. DNA-based antitumor 32 
vaccination was chosen as our first xCT targeting option in light of our consolidated expertise in the 33 
field and of the advantages of DNA vaccines. DNA vaccines were introduced in the early 1990s and 34 
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consisted in the subcutaneous or intramuscular administration of plasmids coding for viral or nonviral 1 
antigens [25]. Plasmids are taken up by resident antigen presenting cells (APC), monocytes and 2 
myocytes, which then express the antigen and present it to T lymphocytes, potentially inducing long-3 
term cellular immunity [26]. When the expressed antigen is soluble or membrane-bound, a humoral 4 
response against it can be eventually mounted by activation of B lymphocytes [7]. Many anti-cancer 5 
DNA vaccines are currently tested in preventive or therapeutic protocols in the pre-clinical setting 6 
[8]. Up to now, no DNA vaccine has been approved by FDA or EMA for use in human cancer patients, 7 
but a few have been licensed for dogs and several clinical trials are ongoing in human patients, some 8 
of them with promising results [27]. DNA vaccination offers many advantages as compared to other 9 
immunotherapies, since DNA vaccines are relatively simple and inexpensive to design and produce 10 
on large scale, and are well tolerated and safe. Indeed, it has been demonstrated in preclinical models 11 
and by many clinical trials that the risk for plasmid genomic integration is very low, and no evidence 12 
of anti-DNA immune response following vaccination have been reported so far, allowing for multiple 13 
administration [8]. In the light of these observations, we generated an xCT-targeting DNA vaccine 14 
(pVAX1-mxCT) by cloning mouse xCT open reading frame (NM_011990.2) in the FDA-approved 15 
pVAX1 plasmid, under the transcriptional control of a CMV promoter. APC have a pivotal role in 16 
immunity induction by DNA vaccines by presenting vaccine-derived peptides on MHC I and II 17 
molecules following either direct transfection of the resident APC at the injection site or DC 18 
engulfment of apoptotic transfected cells and presentation of the produced antigens, inducing CD8+ 19 
and CD4+ T cell activation [7]. Furthermore, plasmid DNA backbone itself acts as a pathogen-20 
associated molecular pattern binding to TLR9 and other cytosolic double-stranded DNA sensors, 21 
eventually contributing to the intrinsic immunogenicity of DNA vaccines [28]. Thus, in theory, DNA 22 
vaccines coding the full sequence of a transmembrane protein should elicit both cellular and humoral 23 
responses against the target antigen. In practice, many hurdles need to be faced to obtain a strong 24 
immune response against a self non-mutated antigen such as xCT. Central tolerance against xCT is 25 
indeed likely to occur, thus depleting highly reactive T cells. However, as observed for another self-26 
antigen subjected to central tolerance (rat Her2 in BALB-neuT mice), thymic depletion occurs mainly 27 
on self-reactive CD8+ T cells [29]. Indeed, the protective immune response elicited in BALB-neuT 28 
mice following administration of the rat Her2 DNA vaccine rests on activation of CD4+ T cells and 29 
the subsequent stimulation of anti-Her2 antibody production [29]. We can speculate that a similar 30 
mechanism takes place after xCT vaccination.  31 
A potential strategy to break T cell tolerance and induce higher humoral and cellular responses is 32 
the use of recombinant viral vector-based vaccines. Indeed, strong immune responses can be induced 33 
by using viruses engineered to express exogenous antigens into host cells. Besides allowing antigen 34 
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presentation to T lymphocytes, virus-based vaccines show the advantage of creating an inflammatory 1 
environment produced by the virus intrinsic immunogenicity. In order to be a potentially translatable 2 
vector, a virus should be safe, easy to manipulate, and able to induce the transgene expression in host 3 
cells long enough to induce a potent immune reaction [30]. 4 
These properties are displayed by bovine herpesvirus 4 (BoHV-4), a member of the 5 
gammaherpesvirinae subfamily, genus Rhadinovirus, that has been isolated from healthy cattle and  6 
successfully used to express exogenous antigens in various cell types. An apathogenic derivative of 7 
BoHV-4, able to deliver genes to mammalian cells but endowed with a reduced replication ability in 8 
order to decrease the cytopathic effect associated to viral replication, was successfully used to 9 
vaccinate mice, rats, goats, rabbits and sheeps without any signs of pathogenicity or oncogenicity 10 
[31]. Moreover, BoHV-4 vaccination overcomes one of the major concerns of viral vectors, i.e. 11 
induction of an anti-viral immune response that gives rise to neutralizing antibodies, precluding the 12 
possibility of multiple administrations. Therefore, we cloned the full length mouse xCT open reading 13 
frame under the control of the CMV promoter in the BoHV-4 vector (BoHV-4-mxCT, Conti et al.,  14 
unpublished). When systemically administered in mice, BoHV-4 gives a persistent infection in 15 
different organs, in particular within the monocyte/macrophage lineage [32], thus generating both 16 
humoral and cellular immune responses [33]. Indeed, we have previously demonstrated that a BoHV-17 
4-based vector delivering a chimeric rat-human Her2 protein was able to induce a higher humoral 18 
response than the corresponding DNA vaccine in BALB-neuT mice, indicating that it is superior to 19 
plasmid DNA vaccination in the activation of B and CD4+ T lymphocytes [33]. Moreover, this BoHV-20 
4 based vaccine induced a 3-fold higher specific cytotoxic response than the DNA vaccine in BALB/c 21 
mice, suggesting that it also possesses a higher ability to activate CD8+ T cells [33]. We therefore 22 
expected that BoHV-4-mxCT could induce high titers of anti-xCT antibodies in BALB/c mice, and 23 
hypothesized that it could also be able to induce a T cytotoxic response. 24 
Another promising strategy to break T cell tolerance with little side effects is represented by 25 
vaccination with Virus-Like Particles (VLP), artificial nanoparticles composed by self-assembled 26 
repetitive structure of viral capsid proteins that lack genetic material. VLP are safe, unable to replicate 27 
or to be pathogenic and they are produced in large-scale systems with minimal costs [34]. VLP have 28 
different applications since they are excellent delivery systems for various drugs and imaging probes 29 
[35]. They are also good candidates as vaccines able to display antigens conjugated to their surface. 30 
Moreover, their small size allows them to pass through the lymphatic vessels and reach the lymph 31 
nodes where they can induce DC antigen presentation through both MHC I and MHC II [34]. These 32 
processes activate cytotoxic CD8+ T cells and either T helper 1 or 2 CD4+ cells [36]. The humoral 33 
response is stimulated by T helper cells or directly by the VLP, since their repetitive structure and 34 
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their antigen display system improve B cell receptor binding, inducing a potent B-cell activation [37]. 1 
VLP also stimulate innate immunity through the activation of Pattern Recognition Receptors 2 
mediated by their residual viral proteins [34]. 3 
Many VLP-based vaccines targeting non-self antigens have been approved by FDA and are 4 
commercially available for the prevention of infectious diseases, including: Engerix-B® and Sci-B-5 
Vac™ against the hepatitis B virus, Gardasil®, Cervarix® and Gardasil9® against the human papilloma 6 
virus, and Mosquirix® against malaria [38]. Many studies also focused on generation of VLP charged 7 
with tumor-associated antigen (TAA) in several preclinical models of cancer [36]. For melanoma 8 
patients, phase II clinical trial on a VLP-based vaccine has now finished with promising results [36]. 9 
By virtue of the encouraging results obtained with these studies, which showed that VLP can break 10 
the immune tolerance in cancer settings, we generated two VLP vaccines based on the RNA 11 
bacteriophage MS2 vector, displaying the third and sixth extracellular domains (ECD3 or ECD6) of 12 
human xCT, respectively named AX09-0M3 and AX09-0M6 [21]. Since mouse and human ECD3 13 
and ECD6 display 73% and 100% identity, respectively, we expected to induce a strong antibody 14 
response directed to xCT extracellular loops. 15 
 16 
Anti-xCT vaccination impairs mammary tumor growth and lung metastatization 17 
To test the efficacy of the different anti-xCT vaccine formulations in hampering mammary cancer 18 
progression, we challenged BALB/c female mice with syngeneic TUBO tumorsphere-derived cells 19 
[19, 21] implanted subcutaneously. When implanted subcutaneously, TUBO cells give rise to Her2+ 20 
tumors with a 100% penetrance and a short latency, reproducing pivotal interactions between tumor 21 
cells and the surrounding microenvironment [39]. They thus represent an interesting preclinical model 22 
to evaluate the efficacy of different immunotherapeutic approaches against tumor growth, both in a 23 
preventive and curative settings.  Mice where then vaccinated with the different vaccine formulations, 24 
twice at two week intervals. In particular, DNA plasmid vaccination was performed by plasmid 25 
intramuscular injection followed by electroporation, which consists in the application of short electric 26 
pulses able to enhance DNA transfection and recruitment of immune cells to the injection site [8]. 27 
BoHV-4 vaccines were administered intraperitoneally, while VLP formulations were injected 28 
intramuscularly (Figure 2). 29 
When subcutaneous tumors were already established (Figure 2a), xCT immunotargeting slowed 30 
tumor growth kinetics, eventually leading to regression in some mice, suggesting that xCT 31 
vaccination may hinder primary tumor growth. Since CSC are involved in the metastatic process, and 32 
it has been demonstrated that system xc- inhibition impairs metastasis formation [40], we tested the 33 
ability of anti-xCT vaccination to prevent  lung colonization by TUBO-derived tumorspheres injected 34 
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intravenously into anti-xCT vaccinated syngeneic BALB/c mice (Figure 2b). All our anti-xCT 1 
vaccines proven to be able to decrease lung colonization [19, 21] (Conti et al. unpublished). 2 
A less artificial metastatic model is represented by the 4T1-cells that, after subcutaneous injection 3 
in syngeneic mice, grow locally and then spontaneously disseminate to distant organs, including the 4 
lungs [41]. Anti-xCT vaccination delivered to mice bearing palpable 4T1 tumorsphere-derived 5 
tumors (Figure 2c) reduced spontaneous lung metastatization [19, 21] (Conti et al. unpublished), 6 
suggesting that xCT targeting may both impair CSC invasive capacity and affect their growth in the 7 
metastatic site.  8 
 9 
Vaccine-induced anti-xCT immune response  10 
The characterization of the immune responses elicited by the different vaccine formulations 11 
revealed that the mechanism of action could be mostly attributed to the generation of a polyclonal 12 
anti-xCT response, as confirmed by their inability to prevent breast cancer metastasis in BALB/c 13 
mice knockout for the μ Ig chain, which do not produce antibodies [19]. We observed an increase of 14 
activation and IFN-γ production in CD4+ T cells from vaccinated mice following re-stimulation of 15 
splenocytes with xCT+ 4T1 cells (Conti et al., unpublished). The induction of a T helper response is 16 
then accompanied by the generation of a polyclonal antibody response against xCT. In particular, we 17 
compared the ability of the different vaccines to induce antibodies able to bind full length mouse or 18 
human xCT proteins, or their extracellular loops ECD3 and ECD6, in ELISA. The results presented 19 
in Figure 3a show that while the empty vector controls BoHV-4-A29, pVAX1 and MS2 did not induce 20 
antibodies able to bind any of the xCT proteins or peptides tested (Figure 3a-e), BoHV-4-mxCT, 21 
pVAX–mxCT and AX09-0M6 vaccines induced the production of antibodies able to recognize the 22 
recombinant mouse xCT (Figure 3a). BoHV-4-mxCT and pVAX–mxCT-induced antibodies also 23 
recognized human xCT recombinant protein, which was also bound by antibodies induced by AX09-24 
0M3 (Figure 3b). Of note, all the vaccines induced antibodies able to bind xCT extracellular domains, 25 
as demonstrated by their ability to bind to xCT ECD6 and to both mouse and human ECD3, with the 26 
highest titers induced by the corresponding VLPs (Figure 3c-e). Moreover, either sera or purified IgG 27 
from mice vaccinated with the different formulations are able to recognize xCT-expressing cells [19, 28 
21] and (Conti et al., unpublished).  29 
Regarding cellular immune response, no detectable activation of CTL against xCT was triggered. 30 
In fact, upon DNA vaccination, we did not observe any specific CD8+ T-cell response (assessed in 31 
an IFN-γ ELISPOT assay) following re-stimulation of splenocytes from anti-xCT vaccinated mice 32 
with the BALB/c MHC class I H-2d dominant mouse xCT peptide [19]. A lack of T cell response 33 
against xCT may be caused by a thymic depletion of high-avidity autoreactive T-cell clones, as we 34 
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have previously reported for the Her2 antigen in the BALB-neuT model [29]. This hypothesis is 1 
strengthened by the fact that in mice vaccinated with a plasmid coding for the human xCT we 2 
observed a strong IFN-γ production following splenocytes re-stimulation with the human 3 
immunodominant xCT peptide (Conti et al., unpublished). Similarly, following vaccination with the 4 
xCT full sequence (Conti et al., unpublished) or with AX09-0M6 [21], we could not observe any 5 
significant increase in the cytotoxic activity of splenocytes against 4T1 cells, indicating that also the 6 
response to sub-dominant peptides was absent. Regarding AX09-0M6 vaccination, this could be due 7 
to the fact that the xCT ECD6 sequence is an octamer, unsuitable to be effectively shown on MHC 8 
class I molecules. Anyway, this lack of a detectable CTL response should not be considered a 9 
limitation in the efficacy of CSC-targeting vaccines, since CSC down regulate MHC class I 10 
expression as an immune evasion mechanism [42]. Thus, CD8+ T lymphocytes are expected to play 11 
only a marginal role in immunotherapies directed to CSC oncoantigens.  12 
Cancer metastasis is a complex and inefficient process that requires disseminated cancer cells to 13 
find the proper microenvironment able to support metastatic growth, and both innate and adaptive 14 
immune cells in the target organ play a key role in this process [43]. Therefore, the anti-metastatic 15 
effect elicited by anti-xCT vaccines could be due, at least in part, to changes in the number and 16 
activities of the immune cells constituting the lung metastatic niche. Indeed, anti-xCT VLP-based 17 
vaccines induced a significant increase in the percentage of NK cells and a trend of increase in the 18 
percentage of T cells in the metastatic lungs [21]. Regarding the myeloid compartment, vaccinated 19 
mice displayed a trend of increase in the percentage of macrophages and a trend of decrease in the 20 
percentage of granulocytic MDSC/neutrophils compared to controls [21]. It has been demonstrated 21 
that breast cancer cells induce neutrophil recruitment in the lung pre-metastatic niche, which 22 
contribute to the growth of lung metastases [44]. Since xCT is expressed on activated neutrophils and 23 
participate to their immunosuppressive activity [45], the possibility that the decrease of neutrophil 24 
population in the lung could be induced by xCT immunotargeting deserves further investigation. 25 
 26 
Biological activity of anti-xCT antibodies induced by vaccination 27 
The anti-xCT antibodies induced by vaccination exert a therapeutic activity through two different 28 
mechanisms, as they i) activate the innate immune response against CSC through the induction of 29 
antibody-dependent cell cytotoxicity (ADCC), and ii) directly impair CSC self-renewal by inhibiting 30 
system xc- activity. Indeed, IgG from vaccinated mice increase the lysis of 4T1 cells by unstimulated 31 
splenocytes, likely NK cells, in vitro [21]. Furthermore, antibodies from vaccinated mice decrease 32 
sphere-generation ability of xCT-expressing cancer cells  The resulting spheres are smaller and 33 
contain a reduced fraction of CSC markers-positive cells compared to tumorsphere-derived cells 34 
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incubated with control mice antibodies [19, 21] (Conti et al., unpublished). Moreover, by inhibiting 1 
system xc- function, anti-xCT antibodies alter CSC redox balance, with a consequent increase in 2 
intracellular ROS levels [19, 21]. Elevated ROS levels negatively affect CSC survival, since they 3 
enhance sensitivity to chemotherapy and radiotherapy, inhibit β-catenin and consequently down-4 
regulate stem cell genes, and promote ferroptosis, a ROS and iron-dependent cell death [46]. Indeed, 5 
sera from vaccinated mice increase the expression of Glutathione-Specific Gamma-6 
Glutamylcyclotransferase 1 (Chac1; Conti et al., unpublished), an enzyme that degrades GSH and has 7 
been linked to ferroptosis and cell death induced by cystine starvation in breast cancer [47].  8 
All these observation support the notion that xCT is not a simple fortuitous feature of the stem-9 
like status, but it plays a functional role in CSC biology and cancer progression, decreasing the 10 
probability that xCT immunotargeting may lead to cancer escape via antigen-loss mechanisms. 11 
 12 
Anti-xCT vaccination does not elicit side effects in vaccinated mice 13 
Targeting self-antigens can raise safety concerns about affecting normal cells and inducing 14 
autoimmune disease. xCT physiological expression is mainly restricted to a few normal cell types, 15 
mostly astrocytes and microglia in the central nervous system [48, 49]. xCT immunotargeting did not 16 
induce any evident adverse effects, and no inflammatory cell infiltrates or any other abnormalities 17 
were detected in the brains of vaccinated mice, maybe due to the protective effect exerted by the 18 
blood-brain barrier. Furthermore, no detectable behavioral changes were observed in vaccinated mice 19 
(Conti et al., unpublished) and [21].  20 
However, system xc- can also regulate immune cell functions, since it mediates cystine uptake in 21 
macrophages and DC, which in turn release cysteine that is essential for T lymphocyte activation 22 
[45]. Nonetheless, the combination of xCT and Her2 immunotherapies did not impair the Her2-23 
specific T-cell response [19], and no reduction in splenic DC, neutrophils, and macrophages was 24 
induced by vaccination [21]. The safety of xCT immunotargeting is further supported by the absence 25 
of alterations in the organs of xCT knockout mice [50]. Also from a functional point of view, xCT-/- 26 
mice show no dramatic phenotypic alterations even in the brain, where xCT is constitutively 27 
expressed, indicating that loss of xCT is largely compensated by other mechanisms in vivo. However, 28 
a role for system xc- emerges under induced pathological conditions. As exhaustively reviewed in 29 
[17], although xCT shows a rather restricted expression pattern under normal conditions in vivo, it is 30 
induced in disease states where oxidative stress and inflammation are present. However, xCT 31 
upregulation may represent a double-edged sword depending on the site of the disease. In the CNS, 32 
xCT upregulation may exacerbate the neuropathological disorders by inducing glutamate-dependent 33 
excitotoxicity in neurons. This could explain why xCT deficiency in xCT-/- mice protects against 34 
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toxin-induced Parkinson disease-like neurodegeneration and reduces susceptibility against limbic 1 
seizures [51, 52]. Moreover, system xc- regulates microglial reactivity in a mouse model of 2 
amyotrophic lateral sclerosis. Here, genetic deletion of xCT slows the progression of the symptoms 3 
and increases the number of surviving motor neurons at the end stage of the disease, eventually 4 
improving survival of mice following the disease onset [53]. Similarly, lack of xCT attenuates 5 
multiple sclerosis symptoms caused by acute autoimmune inflammatory demyelination [54]. 6 
Conversely, deletion of xCT worsens ischemic kidney injury [55], increases lung damage and 7 
mortality following Paraquat administration [56], and aggravates acetaminophen-induced hepatic 8 
damage and mortality [57] compared to wild type mice. This supports a protective role for system xc- 9 
against oxidative stress in tissues where excitotoxicity is not involved [17]. Therefore, possible side 10 
effects of an anti-xCT vaccination could emerge when other pathological states occur. Further 11 
investigations in this regards are surely needed. 12 
 13 
Conclusions and future perspectives 14 
Considering the high potential of CSC to give rise to recurrences and metastasis, the identification 15 
of CSC-associated antigens, such as xCT, offers a reliable chance to design a CSC-directed 16 
immunotherapy aimed at preventing tumor evolution. We believe that our observations are 17 
particularly valuable for the clinical development of anti-CSC immunotherapies, because anti-xCT 18 
vaccination generated a robust humoral response with no toxicity. 19 
Although VLP vaccination induced higher antibody titers as detected by ELISA (Figure 3), the 20 
efficacy of our three vaccines in impairing tumor growth and metastases in vivo was similar, and none 21 
of them was able to completely eradicate the disease [19, 21] (Conti et. al, unpublished). This 22 
observation suggests that xCT immunotargeting, independently on the vector used, could be used as 23 
an adjuvant therapy in breast cancer patients that develop resistance to standard therapies. xCT 24 
immunotargeting may be combined with different conventional or innovative treatments able to either 25 
stimulate immune responses, or to target differentiated cancer cells or CSC. In particular, xCT 26 
targeting could be successfully coupled to chemotherapy. In fact, we observed that tumorspheres 27 
display significantly increased resistance to doxorubicin, a drug largely used in breast cancer therapy, 28 
as compared to cells grown in differentiated conditions [19]. This is not surprising, since system xc- 29 
contributes to resistance of cancer cells to many anti-tumor drugs [58], as many chemotherapeutics, 30 
including doxorubicin, exert their function, at least in part, by increasing intracellular ROS levels 31 
[59]. Furthermore, cancer cells upregulate xCT as a mechanism of self-defense in response to many 32 
chemotherapeutic drugs [58]. Therefore, vaccine-mediated inhibition of system xc- in combination, 33 
or sequentially, with chemotherapy may elicit clinical benefit by sensitizing bulk tumors to 34 
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chemotherapeutic agents as well as by targeting CSC. In support of this hypothesis, we have 1 
demonstrated that combination of anti-xCT DNA vaccination and doxorubicin strongly enhanced the 2 
anti-metastatic and anti-tumor potential of the individual treatments [19].  3 
Furthermore, since PD-L1 is expressed on both CSC and myeloid cells in breast cancer, and we 4 
observed an increase in PD-1 expression on infiltrating lymphocytes upon anti-xCT vaccination 5 
(Conti et al., unpublished), combination with anti-PD1 or PD-L1 monoclonal antibodies may improve 6 
therapeutic efficacy. Many clinical trials are currently testing the administration of anti-PD1 or anti-7 
PD-L1 antibodies in breast cancer patients, and preliminary evidence show clinical activity in a 8 
proportion of triple negative breast cancer  patients treated with the anti-PD1 Pembrolizumab 9 
(Keytruda; Merck; NCT01848834) or the anti-PD-L1 atezolizumab (Tecentriq; Roche).  10 
Despite our observations strongly suggest that anti-xCT vaccination is a feasible approach to 11 
induce anti-tumor protection, the evaluation of the real potential of xCT immunotargeting needs 12 
further study in appropriate preclinical models. Although transplantable tumor models have been 13 
valuable for the understanding of meaningful molecular targets and the consequences of their 14 
immunotargeting, TUBO- and 4T1-derived tumors do not represent the heterogeneity distinctive of 15 
human tumors and, because of their rapid growth rate in syngeneic mice, the long-lasting reciprocal 16 
exchange between cancer and immune cells, fundamental for tumor shaping, is lost [43]. In this view, 17 
BALB-neuT mice represent a better candidate [43]. Thanks to the slow spontaneous progression, 18 
cancer cells in BALB-neuT tumors engage long-lasting relationships with the surrounding 19 
microenvironment, including immune cells. The continuous interplay between the various cell 20 
populations in the tumor allows the generation of niches for CSC and therefore the sustaining of the 21 
tumor evolution [43]. The employment of currently available xCT null mouse models [60] crossed 22 
with BALB-neuT mice would help in dissecting the role of xCT in the CSC niche, as well as in the 23 
different steps of mammary tumor progression, from early to late stages.  24 
Undoubtedly, translation of anti-xCT immunotherapy from the preclinical to the clinical setting 25 
would require a clear indication that xCT targeting would not lead to harmful side effects. As we have 26 
previously discussed, xCT expression in vivo is limited to few tissue types and anti-xCT vaccination 27 
did not lead to any functional or morphological alterations in vaccinated mice. Useful clues also come 28 
from studies performed on xCT-null mice. A review of the existing literature shows that xCT is 29 
dispensable in vivo under physiological condition, as compensatory mechanisms likely counteract the 30 
lack of this transporter [17]. On the contrary, the effects of xCT absence emerge under pathological 31 
conditions, thus requiring further investigations on the effect of anti-xCT vaccination in this context. 32 
In conclusion, we showed that anti-CSC vaccination is feasible and effective in providing 33 
protection against tumor. xCT appears to be an optimal oncoantigen, since it can be targeted by 34 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
antibodies that mediate ADCC and inhibit its biological activity, which is required for CSC self-1 
renewal, chemoresistance and tumor progression. Despite definitive proof for the safety of the vaccine 2 
needs to be provided before translation into the clinic, we are on the right path towards breaking CSC 3 
invulnerability and developing more effective anti-cancer therapies. 4 
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Mice used for the vaccination experiments reported in this paper were purchased from Charles 1 
River Laboratories or bred at the Molecular Biotechnology Center, University of Turin, where all 2 
mice were maintained and treated in accordance with the University Ethical Committee and European 3 
Union guidelines under Directive 2010/63. 4 
 5 
Figure legends 6 
 7 
Figure 1. Topological model of the xc- transporter. xCT is composed by 12 transmembrane 8 
domains spanning the cellular membrane (red cylinders), 7 intracellular and 6 extracellular domains 9 
(ECD1-6, all represented as red lines) and is associated to CD98, the heavy chain of the xc- transporter 10 
spanning the cellular membrane (blue cylinder). A scheme of the xc- transporter function is also 11 
reported, with extracellular cystine (CySS) being imported in exchange for intracellular glutamate 12 
(Glu) and reduced to cysteine, the rate-limiting precursor for the synthesis of GSH, which then 13 
scavenges intracellular ROS. 14 
 15 
Figure 2. Schematic representation of the different vaccination protocols. a) Therapeutic anti-16 
tumor setting. Female BALB/c mice are challenged with a subcutaneous injection of TUBO 17 
tumorsphere-derived cells. When tumors become palpable, mice are vaccinated twice at two-week 18 
interval and tumor growth is monitored for the following days. b) Prophylactic anti-metastasis setting. 19 
Female BALB/c mice are vaccinated twice at two-week interval. One week after the second 20 
vaccination, mice are challenged with an intravenous injection of TUBO tumorsphere-derived cells. 21 
Few weeks after the challenge, mice are euthanized and lungs analyzed for the presence of metastasis. 22 
c) Therapeutic anti-tumor and anti-metastasis setting. Female BALB/c mice are challenged with a 23 
subcutaneous injection of 4T1 tumorsphere-derived cells. When tumors become palpable, mice are 24 
vaccinated twice at two-week interval and the tumor growth is monitored for the following days. Few 25 
weeks after challenge, mice are euthanized and lungs analyzed for the presence of metastasis. 26 
Figure 3. Anti-xCT vaccination induces a specific humoral response. Sera were collected from 27 
BALB/c mice vaccinated twice at two-week interval with either BoHV-4-mxCT, pVAX1-mxCT, 28 
AX09-0M6 or AX09-0M3 or control vectors (pVAX1, BoHV-4-A29 or MS2) were collected two 29 
weeks after the second vaccination, and tested by ELISA on wells coated with: a) full-length mouse 30 
xCT protein, b) full-length human xCT protein, or peptides corresponding to c) mouse/human xCT 31 
ECD6, d) mouse xCT ECD3 and e) human xCT ECD3. ELISA was performed from pools (each 32 
composed by 5 mice) of sera from 6 independent experiments. Graphs show mean ± SEM of the 33 
OD450 of each pool after the subtraction of the OD450 of the corresponding pool from untreated mice. 34 
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Sera from mice vaccinated with the empty vectors did not bind to either full length xCT or its ECD, 1 
while those from BoHV-4-mxCT, pVAX–mxCT, AX09-0M6 and AX09-0M3 vaccinated mice 2 
recognized both recombinant xCT proteins and their ECD, although with variable efficiency.  3 
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